A Peripheral CB1R Antagonist Increases Lipolysis, Oxygen Consumption Rate, and Markers of Beiging in 3T3-L1 Adipocytes Similar to RIM, Suggesting that Central Effects Can Be Avoided

With the increased prevalence of obesity and related co-morbidities, such as type 2 diabetes (T2D), worldwide, improvements in pharmacological treatments are necessary. The brain- and peripheral-cannabinoid receptor 1 (CB1R) antagonist rimonabant (RIM) has been shown to induce weight loss and improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Paszkiewicz, Rebecca L., Bergman, Richard N., Santos, Roberta S., Frank, Aaron P., Woolcott, Orison O., Iyer, Malini S., Stefanovski, Darko, Clegg, Deborah J., Kabir, Morvarid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554772/
https://www.ncbi.nlm.nih.gov/pubmed/32927872
http://dx.doi.org/10.3390/ijms21186639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554772/
https://www.ncbi.nlm.nih.gov/pubmed/32927872
http://dx.doi.org/10.3390/ijms21186639

Ejemplares similares